Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX-2 Regimen and Nivolumab in Recurrent/Metastatic Solid Tumors
NCT03758781Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of citoplurikin in renal cell carcinoma (RCC), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by Moffitt Cancer Center. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Feb 2019; status: completed.
02
Drugs
citoplurikin
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)melanoma
Beyond the preview
Go deeper on NCT03758781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758781.